Tag Archives: patents

FDA Accepts First Biosimilar Application for Review

Posted on July 28, 2014 by Warren Woessner

In an important step forward for the introduction of “generic biological,” the FDA announced that it has accepted Sandoz’s application to market a generic version of Amgen’s Neupogen®, which stimulates white blood cell production. As you may recall, about two years … Continue reading →

Posted in FDA | Tagged , , , , , , , , , , , , | Leave a comment

Abbvie V. Janssen Biotech –Written Description Requirement Road Map

Posted on July 7, 2014 by Warren Woessner

The recent decision in Abbvie Deutschland v. Janssen Biotech and Centorcor Biologics, App. No. 2013-1338, -1346 (Fed. Cir. , July 1, 2014) deserves more attention than it has received. (A copy of the decision is available at the end of … Continue reading →

Posted in Written Description Requirements (WDR) | Tagged , , , , , , , , , | 1 Comment

More Questions Than Answers from the PTO

Posted on July 2, 2014 by Warren Woessner

At the recent BIO International Convention, Deputy Commissioner Andrew Hirschfeld (who chaired the May PTO s.101 Forum) presented seven “Sample Claims” related to biotech/pharma inventions and invited “discussion and feedback” from the interested public. The claims have been posted on … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , | 1 Comment

URGENT – COMMENTS DEADLINE EXTENDED

Posted on June 27, 2014 by Warren Woessner

The deadline for Myriad-Mayo comments has been extended by a month. Info on the USPTO website and can be found here.  

Posted in USPTO Practice and Policy | Tagged , , , , , , , , | Leave a comment